ImmuCell Corp represents a set of core values and a corporate philosophy aimed at advancing animal health and well-being. The company is committed to developing, manufacturing, and selling products that enhance the health and productivity of animals, with a specific focus on the dairy and beef industries. ImmuCell prioritizes quality, innovation, and sustainability, striving to provide effective solutions for preventing and treating various diseases. By leveraging their expertise in animal health, ImmuCell Corp aims to contribute to healthier livestock populations and more efficient farming practices.

ImmuCell Corp is primarily present in the United States.

ImmuCell Corp has achieved significant milestones in its history. One of the notable accomplishments is the development and commercialization of their flagship product, First Defense®. This groundbreaking product has revolutionized the field of animal health by providing a proactive approach to preventing calf scours. Additionally, ImmuCell Corp has successfully expanded its product portfolio to include prominent offerings such as Wipe Out® Dairy Wipes and California Mastitis Test. The company's commitment to research and innovation has garnered recognition, including the prestigious "Best Places to Work in Maine" award. ImmuCell Corp continues to make strides in the animal health industry, solidifying its position as a leader in innovative solutions that enhance herd productivity and profitability.

ImmuCell Corp is a renowned biotechnology company specializing in the development and production of innovative, preventative animal health products, focusing primarily on the dairy and beef industries. Founded in 1982 and headquartered in Portland, Maine, ImmuCell has established itself as a leader in the field of animal health through its dedication to improving the well-being and productivity of livestock. The company's flagship product, First Defense®, helps protect newborn calves against common diseases while enhancing their natural immune system. ImmuCell Corp remains committed to research and development, continuously striving to provide cutting-edge solutions for animal health challenges.

The main competitors of ImmuCell Corp in the market include companies such as Zoetis Inc., Elanco Animal Health Inc., and Merck & Co. Inc.

ImmuCell Corp is primarily active in the animal health industry.

ImmuCell Corp operates as a biotechnology company, focusing on the development and commercialization of products that improve the health and productivity of dairy and beef cattle. The company's business model revolves around providing innovative animal health solutions, such as First Defense® for newborn calves, which helps strengthen their immune system and prevent diseases. ImmuCell Corp also offers Mast Out®, an FDA-approved treatment for mastitis in lactating dairy cows. Through its dedication to science-driven research and development, ImmuCell Corp aims to enhance animal well-being, increase farmers' efficiency, and ultimately contribute to a sustainable agriculture industry.

لا يمكن حساب مضاعف الربحية للسهم لـImmuCell في الوقت الحالي.

لا يمكن حالياً حساب معامل القيمة السوقية إلى العائدات لـ ImmuCell.

نقاط جودة AlleAktien لـ ImmuCell هي 5/10.

لا يمكن حالياً حساب الإيرادات لـImmuCell.

لا يمكن حساب الربح لـ ImmuCell في الوقت الحالي.

ImmuCell Corp is a US company specializing in the development and marketing of products for the prevention and treatment of animal diseases, particularly in the dairy industry. The company operates in two main divisions: animal health and veterinary diagnostics. In the animal health division, the flagship product is Calf-Guard®, an immunoglobulin preparation used for preventing diarrhea in calves. In the veterinary diagnostics division, the Bovine IgG Rapid Test Kit is a key product that allows farmers to monitor the health of their animals and detect diseases in a timely manner. ImmuCell Corp aims to expand its product pipeline and enter new markets.

يوزع ImmuCell أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ ImmuCell في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـImmuCell هو US4525253062.

رمز WKN لـ ImmuCell هو 885825.

الرمز المُختصر لـ ImmuCell هو ICCC.

خلال آخر 12 شهراً، دفعت ImmuCell توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع ImmuCell خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ ImmuCell هي .

ImmuCell يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

ImmuCell دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

ImmuCell يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من ImmuCell المُعلن عنها في ٢٣‏/٧‏/٢٠٢٥، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٣‏/٧‏/٢٠٢٥.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٣‏/٧‏/٢٠٢٥.

في العام 2024، وزعت ImmuCell 0 USD كأرباح أسهم.

يتم توزيع أرباح ImmuCell بالعملة USD.